Etomidate is primarily utilized as an anesthetic agent. On September 11, 2023, the National Medical Products Administration (NMPA) issued an official announcement classifying etomidate—excluding domestically approved pharmaceutical preparations containing the substance—as a Category II psychotropic substance.

To support law enforcement efforts, AccuSift provides high-performance competitive antibody pairs for etomidate detection. These reagents offer exceptional inter-batch consistency and are optimized specifically for IVD kit development, including lateral flow assays, chemiluminescence, ELISA, and POCT platforms. Featuring high affinity and high specificity, they enable rapid and reliable detection.